Four Models of Telephone Support for Stimulant Recovery

Status Completed

Clinical Trial Summary

The overall objective of this research is to develop and refine empirically supported continuing care interventions that promote healthy behavior and sustained abstinence from illicit drug use.

Clinical Trial Description

For treatment interventions to provide the desired result of long term abstinence, it is important to develop strategies to enhance the effectiveness of continued care approaches. We plan to conduct a prospective, randomized comparison of four models of counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program. Some 500 participants completing a 4-month Matrix Outpatient Model of stimulant abuse treatment will be randomly assigned to one of four counseling groups (n=100 per group): (1) unstructured/non-directive, (2) structured/non-directive, (3) unstructured/directive, or (4) structured/directive telephone counseling, or (5) a control group consisting of standard referral to Matrix aftercare, for a total sample size of 500. The two structured conditions will be based on the behavioral "prompts" identified by Farabee et al. (2002)* as being associated with drug avoidance. In the non-directive conditions, subjects will be allowed to state their own goals and how they intend to achieve them. In the directive conditions, the counselor will provide specific recommendations to help the subject adopt as many of the drug-avoidance activities as possible. Outcomes will be tracked for 12 months following completion of primary treatment (a total of 16 months after treatment admission) and will include measurement of participation in drug-avoidance activities (including aftercare participation) as well as self-reported and objective measures of substance use and related behavior change.

*Farabee, D., Rawson, R.A., & McCann, M. (2002). Adoption of drug avoidance activities among patients in contingency management and cognitive-behavioral treatments. Journal of Substance Abuse Treatment, 23, 343-350. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00744068
Study type	Interventional
Source	University of California, Los Angeles
Contact
Status	Completed
Phase	N/A
Start date	April 2006
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02437123` - The Cedar Project: Impact of mHealth for HIV Prevention Among Young Indigenous People Who Use Illicit Drugs	N/A
Completed	`NCT02192931` - A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users	Phase 4
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT02224508` - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks	N/A
Completed	`NCT02939352` - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues	Early Phase 1
Completed	`NCT01685073` - The Role of Sleep in the Treatment of Cannabis Use Disorders	Phase 2/Phase 3
Completed	`NCT01591239` - Home-Based Program to Help Parents of Drug Abusing Adolescents	N/A
Completed	`NCT00317460` - Buprenorphine and Integrated HIV Care	Phase 4
Completed	`NCT03678051` - CBT4CBT for Women in Residential Treatment for Substance Use Disorders	N/A
Completed	`NCT04105621` - Westlake Personalized Nutrition and Health Cohort for Drug Addicts
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A
Completed	`NCT00390559` - Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3	N/A
Completed	`NCT00496990` - Treating the Partners of Drug Using Pregnant Women: Stage II	Phase 2/Phase 3
Completed	`NCT00244699` - Integrating Mindfulness-Based Skills Training Into Brief Outpatient Treatment for Substance Abusing Youth	N/A
Completed	`NCT03402672` - AWAITS: A Web-based E-health Application for Active Illicit Opioid Users	N/A
Completed	`NCT03411265` - RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing	N/A
Completed	`NCT01003496` - Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial	Phase 3
Completed	`NCT02091284` - Bilateral Prefrontal Modulation in Alcoholism	N/A
Completed	`NCT02091167` - Bilateral Prefrontal Modulation in Crack-cocaine Addiction	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.